Skip to content

Study · Systematic review · 2021

2 results

Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.

Cha AS, Chen Y, Fazioli K, Rivara MB, Devine EB

The Journal of clinical endocrinology and metabolism1 Mar 2021Cited by 9 (Europe PMC)

PMID33248440 (opens in a new tab)DOI10.1210/clinem/dgaa894 (opens in a new tab)PepBankPUB-33248440
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found that semaglutide was associated with a lower risk of a composite kidney outcome than placebo, ranking after dapagliflozin, empagliflozin and canagliflozin.

    In plain wordsIn adults with type 2 diabetes, semaglutide was linked to a lower risk of kidney problems than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseComposite kidney outcome
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, dapagliflozin was associated with the greatest reduction in risk of developing the composite kidney outcome (hazard ratio 0.53; 95% credible interval, 0.43-0.66) followed by empagliflozin, canagliflozin, semaglutide, and liraglutide.
    1 context sentence
    Summary · context
    Two independent reviewers selected the 7 eligible studies for analysis.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found that liraglutide was associated with a lower risk of a composite kidney outcome than placebo, ranking after dapagliflozin, empagliflozin, canagliflozin and semaglutide.

    In plain wordsIn adults with type 2 diabetes, liraglutide was linked to a lower risk of kidney problems than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseComposite kidney outcome
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, dapagliflozin was associated with the greatest reduction in risk of developing the composite kidney outcome (hazard ratio 0.53; 95% credible interval, 0.43-0.66) followed by empagliflozin, canagliflozin, semaglutide, and liraglutide.
    1 context sentence
    Summary · context
    Two independent reviewers selected the 7 eligible studies for analysis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.